Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Placing

21 May 2012 07:00

RNS Number : 7108D
ViaLogy PLC
21 May 2012
 



 

ViaLogy PLC ("ViaLogy" or "the Company")

 

Placing of £2.04 million

 

 

London, May 21, 2012. ViaLogy PLC (AIM: VIY), a provider of reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas Exploration and Production (E&P) companies based on proprietary, patented active signal processing technology, is pleased to announce that following a number of new contract wins, it has today conditionally raised a total of £2,045,000 (before expenses) through the placing of 74,363,637 ordinary shares ("the Placing Shares") at a price of 2.75p each ("the Placing") with existing and new institutional investors.

 

The Placing is completing in two tranches, the first being the issue of 38,000,000 Placing Shares at a price of 2.75p each to raise £1,045,000 (before expenses). Application has been made for the admission to trading on AIM of 38,000,000 new ordinary shares, which is expected to take place on 23 May 2012.

 

Following institutional demand, the second tranche is a placing of 36,363,637 Placing Shares at a price of 2.75p each to raise £1,000,000 (before expenses), conditional upon shareholder approval at a general meeting of the Company. A general meeting is expected to be held on or around 15 June 2012. A further announcement will be made in due course.

 

The net proceeds of the Placing will be used to strengthen the balance sheet and provide additional working capital to support ViaLogy's strategy.

 

CEO, Robert W. Dean, commented "2012 is shaping up to be a pivotal year for ViaLogy as we seek to fulfil our goal of widespread E&P industry adoption of our technology, QuantumRD. Since the start of the year we have successfully signed new contracts with three of the largest global E&P firms where QuantumRD will be used in some of the world's most important development fields; aiming to improve significantly on industry-standard techniques now in use. The net funds raised from this placing will provide additional resources as we seek to secure further contracts."

 

"In light of the current difficult market conditions for raising money, I was personally delighted that, following a short round of institutional meetings, we were able to increase the level of the placing due to institutional demand."

 

For the purposes of the Disclosure and Transparency Rules, on admission of the first tranche of the Placing Shares, the Company's total issued share capital consists of 890,243,274 ordinary shares of 1 penny each.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

Options Grant

 

Under the terms of his employment contract entered into on June 22 2010, Dr. Sandeep Gulati, ViaLogy's founder and Chief Technology Officer, is entitled to additional options awards in order to retain his interest in the ordinary share capital of ViaLogy. The Company will therefore issue 7,546,048 options exercisable at 1p per share.

 

 

 

 

 

For further information:

 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe

+44 (0) 1235 834 734

Seymour Pierce (Nominated Advisor and Broker)

+44 (0) 207 107 8000

Mark Percy / Catherine Leftley (Corporate Finance )

Katie Ratner (Corporate Broking)

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEPGUUUAUPPGCU
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.